Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: ImmuCell Corporation

Market Cap 8.76Cr 7.56Cr 6.97Cr 6.52Cr 12Cr 832.39Cr 12Cr 82Cr 32Cr 405.15Cr 33Cr 32Cr 1.4TCr P/E Ratio 2024
-19.5x
P/E Ratio 2025 -51.3x
Enterprise Value 9.7Cr 8.37Cr 7.72Cr 7.22Cr 14Cr 921.62Cr 14Cr 91Cr 36Cr 448.59Cr 36Cr 36Cr 1.55TCr EV / Sales 2024
2.16x
EV / Sales 2025 2.35x
Free-Float
67.45%
Yield 2024 *
-
Yield 2025 -
1 day-0.62%
1 week+0.73%
Current month-5.47%
1 month+15.51%
3 months+46.00%
6 months+55.88%
Current year+57.40%
1 week 9.52
Extreme 9.52
10.15
1 month 8.26
Extreme 8.26
10.75
Current year 5.75
Extreme 5.75
10.75
1 year 4.52
Extreme 4.52
10.75
3 years 3.34
Extreme 3.34
10.75
5 years 3.34
Extreme 3.34
10.96
10 years 0
Extreme 0
13.2
Manager TitleAgeSince
Chief Executive Officer - 01/11/2025
Director of Finance/CFO 46 07/04/2025
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 69 21/12/2006
Director/Board Member 61 31/03/2014
Director/Board Member 66 10/06/2020
Date Insider Type Main position Quantity % Market Cap.
15/04Free

Director

17,899 0.1979%
15/04Other

Director

17,899 0.1979%
15/04Free

Director

11,933 0.1319%
Change 5-day change 1-year change 3-year change Capi.($)
-0.62%+0.73%+51.01%+70.12% 8.76Cr
-2.41%+0.14%+39.53%+154.43% 1,01000Cr
+1.07%+3.48%+53.75%+50.64% 58TCr
+1.32%+0.22%+18.35%+65.35% 40TCr
+0.77%0.00%+19.99%+16.80% 33TCr
-1.42%-1.44%+45.50%+8.37% 29TCr
-0.85%-2.86%+22.05%+13.80% 28TCr
+0.44%+3.48%+24.48%+34.39% 28TCr
+1.66%+1.20%-44.67%-47.49% 20TCr
+0.32%+1.61%+19.48%+63.42% 19TCr
Average -0.32%+0.96%+24.95%+42.98% 35.67TCr
Weighted average by Cap. -0.80%+1.00%+29.84%+66.16%

Financials

2024 2025
Net sales 2.65Cr 2.29Cr 2.11Cr 1.97Cr 3.7Cr 251.82Cr 3.76Cr 25Cr 9.71Cr 122.57Cr 9.94Cr 9.73Cr 424.4Cr 2.76Cr 2.39Cr 2.2Cr 2.06Cr 3.86Cr 262.76Cr 3.92Cr 26Cr 10Cr 127.89Cr 10Cr 10Cr 442.83Cr
Net income -21.57L -18.63L -17.16L -16.07L -30.11L -20Cr -30.58L -2.03Cr -79.02L -9.98Cr -80.94L -79.22L -35Cr -10.4L -9L -8L -8L -14.52L -9.89Cr -14.75L -97.74L -38.11L -4.81Cr -39.03L -38.2L -17Cr
Net Debt 1.13Cr 97.96L 90.27L 84.49L 1.58Cr 107.8Cr 1.61Cr 11Cr 4.16Cr 52Cr 4.26Cr 4.17Cr 181.68Cr 93.88L 81.08L 74.72L 69.94L 1.31Cr 89Cr 1.33Cr 8.82Cr 3.44Cr 43Cr 3.52Cr 3.45Cr 150.38Cr
Logo ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Employees
73
Date Price Change Volume
12/26/12 9.680 $ -0.62% 9,428
11/26/11 9.740 $ +0.72% 10,938
10/26/10 9.670 $ -1.02% 32,413
09/26/09 9.770 $ +0.72% 17,998
08/26/08 9.700 $ +0.94% 20,814
  1. Stock Market
  2. Stocks
  3. ICCC Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!